Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Systemic” Disregard For Basic Dietary Ingredient Rule Troubles FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA dietary supplement program chief Daniel Fabricant surveyed the agency’s top and developing concerns at the SupplySide MarketPlace conference. DMAA and adulterated products reflect a flouting of the principle that only dietary ingredients should occur in supplements, he says.

You may also be interested in...



FDA Ushers Out Known DMAA, Closes Dietary Ingredient Door

USPlabs says it will reformulate its DMAA supplements, although it “stands by the safety and legality” of the products. FDA says “credible science” shows DMAA is not a botanical, not a dietary ingredient and will not be accepted in an NDI notification.

FDA Using “All Available Tools” To Remove DMAA From Market

FDA issues a consumer warning about the potentially lethal effects of DMAA, and promises to use “all available tools at its disposal to ensure the dietary supplements containing” the stimulant “are no longer distributed and available for sale.”

People In Brief

Herbalife brings on Dentali as botanical sciences VP; NACDS expands Nicholson’s role; Innophos announces interim CFO; George Hamilton new face of Infusion Life Sciences; Aker BioMarine names sales VP; Atteryd to chair Food Supplements Europe.

Topics

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel